[1] De La Vieja A, Dohan O, Levy O, et al. Molecular analysis of the sodium/iodide symporter:impact on thyroid and extrathyroid pathophysiology[J]. Physiol Rev, 2000, 80(3):1083-1105.
[2] Spitzweg C, Joba W, Eisenmenger W, et al. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa[J]. J Clin Endocrinol Metab, 1998, 83(5):1746-1751.
[3] Huang M, Batra RK, Kogai T, et al. Ectopie expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer[J]. Cancer Gene Ther, 2001, 8(8):612-618.
[4] Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers[J]. Thyroid, 2002, 12(1):19-26.
[5] Wenzel A, Upadhyay G, Schmitt TL, et al. Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS[J]. Mol Cell Endocrinol, 2003, 213(1):99-108.
[6] Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res, 1999, 59(9):2136-2141.
[7] Spitzweg C, O'Connor MK, Bergert ER, et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter[J]. Cancer Res, 2000, 60(22):6526-6530.
[8] Kakinuma H, Bergert ER, Spitzweg C, et al. Probasin promoter (ARR (2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer[J]. Cancer Res, 2003, 63(22):7840-7844.
[9] Dwyer RM, Bergen ER, O'Connor MK, et al. In vivo radioiodide imaging and treatment of breast cancer xenografis after MUC1-driven expression of the sodium iodide symporter[J]. Clin Cancer Res, 2005, 11(4):1483-1489.
[10] Dwyer RM, Bergert ER, O'Connor MK, et al. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice[J]. Gene Ther, 2006, 13(1):60-66.
[11] Sieger S, Jiang S, Schonsiegel F, et al. Tumour-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3)[J]. Eur J Nucl Med Mol Imaging, 2003, 30(5):748-756.
[12] Dingli D, Diaz RM, Bergert ER, et al. Genetically targeted radiotherapy for multiple myeloma[J]. Blood, 2003, 102(2):489-496.
[13] Schipper ML, Weber A, Behe M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells[J]. Cancer Res, 2003, 63(6):1333-1338.
[14] Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer[J]. Gene Ther, 2005, 12(3):272-280.
[15] Cengic N, Baker CH, Schǚtz M, et al. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression[J]. J Clin Endocrinol Metab, 2005, 90(8):4457-4464.
[16] Schmutzler C, Winzer R, Meissner-Weigl J, et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells[J]. Biochem Biophys Res Commun, 1997, 240(3):832-838.
[17] Kogai T, Schahz JJ, Johnson LS, et al. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line[J]. Proe Natl Acad Sci USA, 2000, 97(15):8519-8524.
[18] Kogai T, Kanamoto Y, Che LH, et al. Systemic retinoic acid treatment induces sodium/iodide symporter expression and radioiodide uptake in mouse breast cancer models[J]. Cancer Res, 2004, 64(1):415-422.
[19] Spitzweg C, Scholz IV, Bergert ER, et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells[J]. Endocrinology, 2003, 144(8):3423-3432.
[20] Unterholzner S, Willhauck MJ, Cengic N, et al. Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells[J]. J Clin Endocrinol Metab, 2006, 91(1):69-78.
[21] Dadachova E, Bouzahzah B, Zuckier LS, et al. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)[J]. Nucl Med Biol, 2002, 29(1):13-18.
[22] Carlin S, Akabani G, Zalutsky MR. In vitro eytotoxieity of (211)atastatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter[J]. J Nucl Med,2003,44(11):1827-1838.
[23] Dwyer RM, Schatz SM, Bergert ER, et al. A preclinieal large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer[J]. Mol Ther, 2005, 12(5):835-841.